Galena Biopharma Inc  

(Public, NASDAQ:GALE)   Watch this stock  
0.000 (0.00%)
Feb 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.73 - 0.75
52 week 0.72 - 49.80
Open 0.73
Vol / Avg. 1.25M/2.90M
Mkt cap 24.14M
P/E     -
Div/yield     -
EPS -2.32
Shares 32.19M
Beta 2.71
Inst. own 9%
Mar 8, 2017
Q4 2016 Galena Biopharma Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 30, 2017
Galena Biopharma Inc at Noble Financial Emerging Growth Investor Conference
Jan 9, 2017
Galena Biopharma Inc at EBD Group Biotech Showcase
Dec 1, 2016
Galena Biopharma Inc at PR Newswire and BetterInvesting (NAIC) Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -23.76% -47.91%
Return on average equity -78.71% -154.06%
Employees 22 -
CDP Score - -


4640 SW Macadam Ave Ste 270
PORTLAND, OR 97239-4232
United States - Map
+1-855-8554253 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system to seek out and attack any residual cancer cells.

Officers and directors

Sanford J. Hillsberg J.D. Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Stephen F. Ghiglieri Chief Financial Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Thomas J. Knapp Interim General Counsel, Corporate Secretary
Age: 63
Bio & Compensation  - Reuters
William L. Ashton Independent Director
Age: 65
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
Irving M. Einhorn Independent Director
Age: 74
Bio & Compensation  - Reuters
Stephen S. Galliker CPA Independent Director
Age: 69
Bio & Compensation  - Reuters
Mary Ann Gray Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters